Literature DB >> 31873297

GeVIR is a continuous gene-level metric that uses variant distribution patterns to prioritize disease candidate genes.

Nikita Abramovs1,2, Andrew Brass1,3, May Tassabehji4,5.   

Abstract

With large-scale population sequencing projects gathering pace, there is a need for strategies that advance disease gene prioritization1,2. Metrics that provide information about a gene and its ability to tolerate protein-altering variation can aid in clinical interpretation of human genomes and can advance disease gene discovery1-4. Previous reported methods analyzed the total variant load in a gene1-4, but did not analyze the distribution pattern of variants within a gene. Using data from 138,632 exome and genome sequences2, we developed gene variation intolerance rank (GeVIR), a continuous gene-level metric for 19,361 genes that is able to prioritize both dominant and recessive Mendelian disease genes5, that outperforms missense constraint metrics3 and that is comparable-but complementary-to loss-of-function (LOF) constraint metrics2. GeVIR is also able to prioritize short genes, for which LOF constraint cannot be estimated with confidence2. The majority of the most intolerant genes identified here have no defined phenotype and are candidates for severe dominant disorders.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31873297     DOI: 10.1038/s41588-019-0560-2

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  7 in total

1.  Promoter CpG Density Predicts Downstream Gene Loss-of-Function Intolerance.

Authors:  Leandros Boukas; Hans T Bjornsson; Kasper D Hansen
Journal:  Am J Hum Genet       Date:  2020-08-14       Impact factor: 11.025

2.  No preferential mode of inheritance for highly constrained genes.

Authors:  Alexandre Fabre; Julien Mancini
Journal:  Intractable Rare Dis Res       Date:  2022-02

3.  Delineation of a novel neurodevelopmental syndrome associated with PAX5 haploinsufficiency.

Authors:  Yoel Gofin; Tianyun Wang; Madelyn A Gillentine; Tiana M Scott; Aliska M Berry; Mahshid S Azamian; Casie Genetti; Pankaj B Agrawal; Jonathan Picker; Monica H Wojcik; Mauricio R Delgado; Sally A Lynch; Stephen W Scherer; Jennifer L Howe; Carlos A Bacino; Stephanie DiTroia; Grace E VanNoy; Anne O'Donnell-Luria; Seema R Lalani; William D Graf; Jill A Rosenfeld; Evan E Eichler; Rachel K Earl; Daryl A Scott
Journal:  Hum Mutat       Date:  2022-01-30       Impact factor: 4.700

4.  Impaired eIF5A function causes a Mendelian disorder that is partially rescued in model systems by spermidine.

Authors:  Víctor Faundes; Martin D Jennings; Siobhan Crilly; Sarah Legraie; Sarah E Withers; Sara Cuvertino; Sally J Davies; Andrew G L Douglas; Andrew E Fry; Victoria Harrison; Jeanne Amiel; Daphné Lehalle; William G Newman; Patricia Newkirk; Judith Ranells; Miranda Splitt; Laura A Cross; Carol J Saunders; Bonnie R Sullivan; Jorge L Granadillo; Christopher T Gordon; Paul R Kasher; Graham D Pavitt; Siddharth Banka
Journal:  Nat Commun       Date:  2021-02-05       Impact factor: 14.919

5.  Redefining germline predisposition in children with molecularly characterized ependymoma: a population-based 20-year cohort.

Authors:  Jon Foss-Skiftesvik; Ulrik Kristoffer Stoltze; Karin Wadt; René Mathiasen; Thomas van Overeem Hansen; Lise Barlebo Ahlborn; Erik Sørensen; Sisse Rye Ostrowski; Solvej Margrete Aldringer Kullegaard; Adrian Otamendi Laspiur; Linea Cecilie Melchior; David Scheie; Bjarne Winther Kristensen; Jane Skjøth-Rasmussen; Kjeld Schmiegelow
Journal:  Acta Neuropathol Commun       Date:  2022-08-25       Impact factor: 7.578

Review 6.  Strategies to Uplift Novel Mendelian Gene Discovery for Improved Clinical Outcomes.

Authors:  Eleanor G Seaby; Heidi L Rehm; Anne O'Donnell-Luria
Journal:  Front Genet       Date:  2021-06-17       Impact factor: 4.599

7.  CADD-Splice-improving genome-wide variant effect prediction using deep learning-derived splice scores.

Authors:  Philipp Rentzsch; Max Schubach; Jay Shendure; Martin Kircher
Journal:  Genome Med       Date:  2021-02-22       Impact factor: 11.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.